Drugs / Calcium folinate
Calcium folinate
Trials 28
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06478238 | Jul 2024 → May 2030 expected | hereditary spastic paraplegia | Shanghai 6th People's Hospital | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06544655 | Oct 2024 → Oct 2027 expected | cancer | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05111860 | Nov 2022 → Aug 2024 | rectal cancer | Shanghai Minimally Invasive Surgery Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT04126655 | Feb 2020 → Oct 2021 | colorectal cancer | Vastra Gotaland Region | Unknown | No outcome recorded |
| Phase 1/2 | NCT03577704 | Aug 2018 → Sep 2022 | cancer | Shanghai Henlius Biotech | Completed | No outcome recorded |
| Phase 1/2 | NCT03633734 | Jul 2018 → Aug 2023 | chemotherapy-induced toxicity, pancreatic adenocarcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT07469956 | Mar 2026 → Jan 2028 expected | pancreas disorder | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06993025 | May 2025 → Apr 2026 overdue | biliary tract cancer | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06648525 | Oct 2024 → Apr 2027 expected | intrahepatic cholangiocarcinoma | Harbin Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06475326 | Jun 2024 → Jun 2025 overdue | malignant pancreatic neoplasm | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06363552 | May 2024 → Apr 2025 | colorectal cancer | Tianshu Liu | Unknown | No outcome recorded |
| Phase 2 | NCT05833126 | Dec 2023 → Dec 2024 | — | Shuhong Yi | Unknown | No outcome recorded |
| Phase 2 | NCT06099951 | Nov 2023 → Sep 2024 overdue | colorectal cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05713838 | Aug 2023 → Dec 2025 overdue | esophageal adenocarcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting | No outcome recorded |
| Phase 2 | NCT05640726 | May 2023 → May 2024 | rectal cancer | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05753163 | Aug 2022 → Mar 2024 | metastasis from malignant tumor of colon | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT00591045 | Jan 2008 → Dec 2012 | gastric cancer | Peking University | Unknown | No outcome recorded |
| Phase 39 trials · 1 met primary | ||||||
| Phase 3 | NCT07238283 | Dec 2025 → Oct 2028 expected | — | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06217042 | Feb 2024 → Mar 2027 expected | malignant pancreatic neoplasm | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05751850 | Jun 2023 → Dec 2024 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05610332 | Nov 2022 → Nov 2024 overdue | gastric cancer | Fujian Medical University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05015621 | Sep 2021 → May 2025 | neuroendocrine carcinoma | Hutchison Medipharma Limited | Unknown | No outcome recorded |
| Phase 3 | NCT04460352 | Nov 2020 → Dec 2026 expected | esophageal squamous cell carcinoma | Karolinska University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT04375605 | Jun 2020 → Jun 2026 | gastroesophageal junction adenocarcinoma | University Medical Center Mannheim | Completed | No outcome recorded |
| Phase 3 | NCT03529279 | Jun 2018 → Jun 2026 | nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT03192618 | Jul 2017 → Dec 2022 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | Met primary |
| Phase not applicable2 trials | ||||||
| — | NCT04198051 | Dec 2019 → Dec 2020 | colon carcinoma, gastric cancer | The First Affiliated Hospital of Dalian Medical University | Unknown | No outcome recorded |
| — | NCT01758666 | Sep 2012 → Nov 2016 | osteosarcoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Comparator or background therapy47 trials | ||||||
| Phase 1 | NCT07594964 Background | Aug 2025 → Oct 2029 expected | biliary tract cancer, gastric cancer, hepatocellular carcinoma, pancreatic ductal adenocarcinoma | Shenzhen Xinhe Biomedical | Recruiting | No outcome recorded |
| Phase 1 | NCT07543744 Background | Apr 2025 → May 2026 overdue | colorectal cancer | R-Pharm | Recruiting | No outcome recorded |
| Phase 1 | NCT03258762 Background | Sep → Nov 2017 | toxoplasmosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT07056777 Background | Mar 2025 → Apr 2027 expected | digestive system cancer | Zhejiang Doer Biologics Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06703177 Background | Feb 2025 → Jan 2026 overdue | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05846867 Background | May 2023 → May 2026 overdue | colorectal cancer | Akeso | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01987102 Background | Dec 2013 → Jan 2017 | osteosarcoma | Isofol Medical AB | Completed | No outcome recorded |
| Phase 2 | NCT07621497 Comparator | Jun 2026 → Jun 2029 expected | metastatic malignant neoplasm in the colon | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07441369 Background | May 2026 → Apr 2027 expected | metastasis from malignant tumor of colon | Fudan University | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT07229846 Background | Feb 2026 → Feb 2027 expected | colorectal cancer | Yanqiao Zhang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07015242 Background | Nov 2025 → Jan 2028 expected | lymphoma | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07106034 Background | Aug 2025 → Jul 2027 expected | colorectal cancer | Shanghai Pudong Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06493760 Background | Sep 2024 → Jun 2025 overdue | colorectal cancer | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06531278 Background | Jul 2024 → Dec 2026 expected | digestive system carcinoma | Jiang Long | Recruiting | No outcome recorded |
| Phase 2 | NCT06242418 Background | Mar 2024 → Dec 2025 overdue | colon carcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06345300 Background | Mar → Dec 2024 | pancreatic exocrine neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT06154538 Background | Nov 2023 → Nov 2026 expected | colorectal carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06239870 Background | Apr 2023 → Sep 2025 | — | Yunnan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06313801 Background | Jan 2023 → Jul 2026 overdue | gastric cancer | Nizhny Novgorod Regional Clinical Oncology Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05684211 Background | Jan 2023 | colorectal cancer | Shanghai Celfuture Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05480280 Background | Jul 2022 → Dec 2023 | colorectal cancer | Sixth Affiliated Hospital, Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT06094140 Background | May 2022 → Jun 2024 overdue | pancreatic adenocarcinoma | Australasian Gastro-Intestinal Trials Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04245865 Background | Jun 2020 → Mar 2025 overdue | colorectal cancer | Vejle Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03567629 Background | May 2018 → Dec 2021 | colorectal cancer | Peking University | Unknown | No outcome recorded |
| Phase 2 | NCT03485027 Background | Jan 2018 → Dec 2022 | chemotherapy-induced toxicity, colorectal cancer | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT02820857 Comparator | Sep 2017 → Aug 2022 | neuroendocrine carcinoma | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 2 | NCT02705300 Background | May 2016 → Aug 2019 | colorectal cancer | Vejle Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01679327 Background | Mar 2012 → Jun 2014 | colorectal cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT06758830 Background | Jan 2025 → Dec 2029 expected | rectal cancer | National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos | Recruiting | No outcome recorded |
| Phase 3 | NCT07595913 Comparator | Jul 2026 → Jun 2028 expected | neuroendocrine carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07412613 Comparator | Apr 2026 → Jun 2030 expected | colorectal cancer | Akeso | Recruiting | No outcome recorded |
| Phase 3 | NCT07328919 Comparator | Jan 2026 → Dec 2029 expected | intrahepatic cholangiocarcinoma | TransThera Sciences (Nanjing), Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07262567 Comparator | Dec 2025 → Jun 2027 expected | malignant pancreatic neoplasm | Genfleet Therapeutics (Shanghai) Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06402708 Background | Apr 2024 → May 2027 expected | thymic carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05768503 Comparator | Mar 2023 → Jan 2026 overdue | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05652894 Comparator | Feb 2023 → Jun 2026 overdue | colorectal cancer | Taizhou Hanzhong Biomedical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04835142 Background | Dec 2020 → Mar 2023 | colorectal cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT03192644 Background | Jul 2017 → Dec 2022 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT03288987 Background | Oct 2016 → Jul 2018 | colorectal cancer | AryoGen Pharmed Co. | Completed | Met primary |
| Phase 3 | NCT02785146 Background | Jun 2016 → Jan 2018 | colorectal cancer | Sixth Affiliated Hospital, Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT00497107 Comparator | Jul 2007 → May 2013 | colorectal cancer | Iwate Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT00349076 Background | Jul 2006 → Dec 2015 | rectal neoplasm | University of Erlangen-Nürnberg Medical School | Completed | Met primary |
| Phase 3 | NCT00385970 Comparator | Mar 2006 → Apr 2015 | colorectal cancer | Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group | Unknown | No outcome recorded |
| Phase 4 | NCT07446465 Background | Mar 2026 → Jan 2027 expected | colorectal cancer | Ye Xu | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06269445 Background | Jan 2024 → Feb 2025 | colorectal cancer | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| — | NCT07114666 Background | Aug 2025 → Aug 2029 expected | malignant pancreatic neoplasm | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| — | NCT00517894 Background | — | lymphoma | Study Group of Medical Tumour Therapy (AGMT) | No longer available | Met primary |
Press releases naming this drug 3 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 75 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Calcium Folinate | “Patients were randomly assigned (1:1; block size of three), without stratification, to receive FOLFIRI (irinotecan 180 mg/m2, calcium folinate 400 mg/m2 or levofolinate 200...” PMID 36739879 ↗ Feb 202375“A Randomised Phase II Study Investigating Two Doses of Arfolitixorin Compared to Calciumfolinate Together With 5- Fluorouracil on TS Inhibition in Tumour and Adjacent Hepatic...” NCT04126655 ↗ “The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400...” NCT05768503 ↗ “This is a randomized phase II multicenter controlled study of oxaliplatin, calcium folinate, and 5-fluorouracil (mFOLFOX7) as neoadjuvant chemotherapy for resectable advanced...” NCT00591045 ↗ “The FOLFOXIRI regimen includes irinotecan 165mg/m2, oxaliplatin 85mg/m2, calcium folinate 200mg/m2 on day 1, followed by continuous intravenous infusion of 5-FU 2400mg/m2/day...” NCT06099951 ↗ “Bevacizumab 5mg/kg d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles” NCT05111860 ↗ “Docetaxel 50mg/m2, ivgtt, d1; Oxaliplatin 85 mg/m2, ivgtt, d1; Calcium folinate 200mg/m2, ivgtt, d1; 5-fluorouracil 2600mg/m2, 24h civ, d1,” NCT05610332 ↗ “50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² fluorouracil as 24 h-infusion, 2 cycles” NCT05713838 ↗ “combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab” NCT03567629 ↗ “Calcium folinate: give irinotecan at a dose of 400mg/m2 by intravenous drip in conjunction with irinotecan infusion” NCT06269445 ↗ “Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.” NCT03577704 ↗ |
| Known as | calcium levofolinate | “400mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1” NCT05480280 ↗ |
| Known as | folinic acid | “Calcium folinate (folinic acid) 20 mg/m2/day intravenously on days 1-4 and 33-35.” NCT06758830 ↗ |
| Known as | leucovorin | “Calcium folinate (leucovorin)” NCT06094140 ↗ |
| Route | Oral | “75 mg, PO from day 1 to day 28 of each 35 day cycle.” NCT00385970 ↗ |